Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 205 to 206 of 206 entries
Sorted by: Best Match Show Resources per page
Systemic anticoagulation is associated with decreased mortality and morbidity in acute pancreatitis.

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]

Kröner PT, Wallace MB, Raimondo M, Antwi SO, Ma Y, Li Z, Ji B, Bi Y.
PMID: 34518096
Pancreatology. 2021 Dec;21(8):1428-1433. doi: 10.1016/j.pan.2021.09.003. Epub 2021 Sep 08.

BACKGROUND/OBJECTIVES: Acute pancreatitis (AP) is a procoagulant state, and markers of coagulopathy are associated with AP severity. We aimed to explore the association of systemic anticoagulation therapy before AP onset with the inpatient outcomes of patients with acute pancreatitis.METHODS:...

Cite
Kröner PT, Wallace MB, Raimondo M, et al. Systemic anticoagulation is associated with decreased mortality and morbidity in acute pancreatitis. Pancreatology. 2021;21(8):1428-1433doi: 10.1016/j.pan.2021.09.003.
Kröner, P. T., Wallace, M. B., Raimondo, M., Antwi, S. O., Ma, Y., Li, Z., Ji, B., & Bi, Y. (2021). Systemic anticoagulation is associated with decreased mortality and morbidity in acute pancreatitis. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 21(8), 1428-1433. https://doi.org/10.1016/j.pan.2021.09.003
Kröner, Paul T, et al. "Systemic anticoagulation is associated with decreased mortality and morbidity in acute pancreatitis." Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] vol. 21,8 (2021): 1428-1433. doi: https://doi.org/10.1016/j.pan.2021.09.003
Kröner PT, Wallace MB, Raimondo M, Antwi SO, Ma Y, Li Z, Ji B, Bi Y. Systemic anticoagulation is associated with decreased mortality and morbidity in acute pancreatitis. Pancreatology. 2021 Dec;21(8):1428-1433. doi: 10.1016/j.pan.2021.09.003. Epub 2021 Sep 08. PMID: 34518096.
Copy Download .nbib Format: NLM
Biomarkers for Immunotherapy of Oral Squamous Cell Carcinoma: Current Status and Challenges.

Frontiers in oncology

Almangush A, Leivo I, Mäkitie AA.
PMID: 33763354
Front Oncol. 2021 Mar 08;11:616629. doi: 10.3389/fonc.2021.616629. eCollection 2021.

Oral squamous cell carcinoma (OSCC) forms a major health problem in many countries. For several decades the management of OSCC consisted of surgery with or without radiotherapy or chemoradiotherapy. Aiming to increase survival rate, recent research has underlined the...

Cite
Almangush A, Leivo I, Mäkitie AA. Biomarkers for Immunotherapy of Oral Squamous Cell Carcinoma: Current Status and Challenges. Front Oncol. 2021;11:616629doi: 10.3389/fonc.2021.616629.
Almangush, A., Leivo, I., & Mäkitie, A. A. (2021). Biomarkers for Immunotherapy of Oral Squamous Cell Carcinoma: Current Status and Challenges. Frontiers in oncology, 11616629. https://doi.org/10.3389/fonc.2021.616629
Almangush, Alhadi, et al. "Biomarkers for Immunotherapy of Oral Squamous Cell Carcinoma: Current Status and Challenges." Frontiers in oncology vol. 11 (2021): 616629. doi: https://doi.org/10.3389/fonc.2021.616629
Almangush A, Leivo I, Mäkitie AA. Biomarkers for Immunotherapy of Oral Squamous Cell Carcinoma: Current Status and Challenges. Front Oncol. 2021 Mar 08;11:616629. doi: 10.3389/fonc.2021.616629. eCollection 2021. PMID: 33763354; PMCID: PMC7982571.
Copy Download .nbib Format: NLM
Showing 205 to 206 of 206 entries